AI assistant
VALIRX PLC — AGM Information 2016
Jun 20, 2016
7998_dva_2016-06-20_b20e3bca-f487-472c-b58e-7b209709fc65.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7198B
ValiRx PLC
20 June 2016
ValiRx Plc
("ValiRx" or "the Company")
RESULT OF ANNUAL GENERAL MEETING
London, UK, 20th June 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces that at its Annual General Meeting ("AGM") held earlier today, Resolutions 1 to 5 were passed. Resolution 6, whilst supported by the majority of Shareholders, did not receive the necessary level of support to be passed at this time. A further announcement will follow in due course.
*** ENDS ***
For more information, please contact:
| ValiRx plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
| Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
| Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 [email protected] |
| Mark Treharne, Corporate Development Manager | Tel: +44 (0) 7736 564 686 [email protected] |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0) 20 7148 7900 |
| Liam Murray | |
| Northland Capital Partners Limited (Joint Broker) | Tel: +44 (0) 203 861 6625 |
| Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking) |
|
| Beaufort Securities Limited (Joint Broker) | Tel: +44 (0) 207 382 8300 |
| Jon Belliss |
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSEEFDSFMSEEM